Real Time Touch



new TOP 200 Companies filing patents this week

new Companies with the Most Patent Filings (2010+)




Real Time Touch

Pfizer Inc patents (2018 archive)


Recent patent applications related to Pfizer Inc. Pfizer Inc is listed as an Agent/Assignee. Note: Pfizer Inc may have other listings under different names/spellings. We're not affiliated with Pfizer Inc, we're just tracking patents.

ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 | Company Directory "P" | Pfizer Inc-related inventors


Dosage regimen for madcam antagonists

The present invention provides a method for the treatment of a patient comprising administering to the patient an initial dose of between about 1 mg and about 150 mg of a madcam antagonist antibody. Biomarkers for assessing a patient's response to anti-madcam treatment are also provided.. ... Pfizer Inc

Sulfonamide-substituted indole modulators of rorc2 and methods of use thereof

The present invention provides sulfonamide-substituted indoles and methods of use thereof-substituted pyrro-lopyridines, pharmaceutical compositions thereof methods of modulating rory activity and/or reducing the amount of il-17 in a subject, and methods of treating various medical disorders using such indoles and pharmaceutical compositions thereof.. . ... Pfizer Inc

Cells and method of cell culture

The invention relates to a method of cell culture where the cells are modified to reduce the level of synthesis of growth and/or productivity inhibitors by the cell. The invention also relates to a method of cell culture for improving cell growth and productivity, in particular in fed-batch culture of mammalian cells at high cell density. ... Pfizer Inc

Crystalline form of lorlatinib free base

This invention relates to acrystalline form of (10r)-7-amino-12-fluoro-2,10,16-trimethyl-5-oxo-10,15,16,17-tetrahydro-2h-8,4-(metheno)pyrazolo[4,3-h] [2,5,11]benzoxadiazacyclo-tetradecine-3-carbonitrile (lorlatinib) free base (form 7). This invention also relates to pharmaceutical compositions comprising form 7, and to methods of using form 7 and such compositions in the treatment of abnormal cell growth, such as cancer, in a mammal.. ... Pfizer Inc

Dual-ended lip balm container

A three to six sided lip balm applicator of the present invention comprises a cap, a liner, and a base, having engagement assemblies for engaging the cap to the liner the liner to the base, and a base from one lip balm applicator to an equivalent base from another lip balm applicator to form a lip balm container. The base comprises a partition with stabilizers which emerge from the partition and extend radially toward and overhang an aperture in the partition, the lip balm applicator may contain a domed lip balm, filled directly into the lip balm applicator or components thereof as a mold for manufacturing the domed lip balm, filled to a fill level approaching the partition top but not touching the partition top.. ... Pfizer Inc

Bicyclic-fused heteroaryl or aryl compounds

Compounds, tautomers and pharmaceutically acceptable salts of the compounds of formula (ia) are disclosed which are inhibitors of interleukin-1 receptor associated kinase (irak4). Methods of treatment, methods of synthesis, and intermediates are also disclosed as defined in the specification.. ... Pfizer Inc

Synergistic auristatin combinations

This invention relates to combinations of an auristatin or an auristatin-based antibody-drug-conjugate (adc) with second active agents including pi3k/mtor inhibitors, mek inhibitors, taxanes, or other anti-cancer agents, and methods of treating abnormal cell growth by administering these combinations to patients.. . ... Pfizer Inc

Glycoconjugation processes and compositions

The invention provides etec linked glycoconjugates comprising a saccharide covalently conjugated to a carrier protein through a (2-((2-oxoethyl)thio)ethyl)carbamate (etec) spacer, immunogenic compositions comprising such glycoconjugates, and methods for the preparation and use of such glycoconjugates and immunogenic compositions.. . ... Pfizer Inc

Reversal agents for fxia inhibitors

The disclosure provides compositions and methods for counteracting the effects of direct activated factor xi (fxia) inhibitors in a subject by administering a variant of fxia.. . ... Pfizer Inc

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to a composition including a factor h binding protein (fhbp) and a neisseria meningitidis non-serogroup b capsular polysaccharide. The invention further relates to uses of a composition that includes fhbp, such as, for example, uses to elicit an immune response against n. ... Pfizer Inc

Solid dosage forms of palbociclib

. . . . The present invention relates to solid dosage forms of palbociclib comprising a water-soluble acid. The dosage forms described herein have desirable pharmacokinetic characteristics.. ... Pfizer Inc

4-1bb binding molecules

. . The present disclosure provides isolated binding molecules that bind to human 4-1bb, nucleic acid molecules encoding an amino acid sequence of the binding molecules, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of making the binding molecules, pharmaceutical compositions containing the binding molecules, and methods of using the binding molecules or compositions.. . ... Pfizer Inc

Tofacitinib oral sustained release dosage forms

The present invention relates to oral sustained release formulations of tofacitinib and pharmaceutical acceptable salts thereof. The formulations described herein have desirable pharmacokinetic characteristics.. ... Pfizer Inc

Bispecific antibodies

The present invention relates to engineered heteromultimeric proteins, and more specifically, to methods for producing and purifying heterodimeric proteins, such as bispecific antibodies and. Methods for producing and purifying such engineered heterodimeric proteins and their use in diagnostics and therapeutics are also provided. ... Pfizer Inc

06/28/18 / #20180177864

Rsv f protein mutants

The present disclosure relates to rsv f protein mutants, nucleic acids or vectors encoding a rsv f protein mutant, compositions comprising a rsv f protein mutant or nucleic acid, and uses of the rsv f protein mutants, nucleic acids or vectors, and compositions.. . ... Pfizer Inc

06/21/18 / #20180171018

Therapeutic antibodies and their uses

The present invention relates to antibodies, e.g., full length antibodies or antigen binding fragments thereof, that specifically bind to bcma (b-cell maturation antigen) and/or cd3 (cluster of differentiation 3). The invention also relates to antibody conjugates (e.g., antibody-drug-conjugates) comprising the bcma antibodies, compositions comprising the bcma antibodies, and methods of using the bcma antibodies and their conjugates for treating conditions associated with cells expressing bcma (e.g., cancer or autoimmune disease). ... Pfizer Inc

06/21/18 / #20180170999

Btla fusion protein agonists and uses thereof

The present invention is based on the seminal discovery that btla agonist fusion proteins modulate an immune response. Specifically, the present invention provides fusion proteins that bind btla enhancing btla signaling the present invention further provides methods of treating cancer and immune and inflammatory diseases and disorders with a btla agonist fusion protein as described herein.. ... Pfizer Inc

06/21/18 / #20180170928

Methyl- and trifluoromethyl-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof

The present invention provides methyl- and trifluoromethyl-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating rorγ activity and/or reducing the amount of il-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.. . ... Pfizer Inc

06/21/18 / #20180170908

Glp-1 agonists and uses thereof

Provided herein are 6-carboxylic acids of benzimidazoles and 4-aza-, 5-aza-, 7-aza- and 4,7-diaza-benzimidazoles as glp-1r agonists, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.. . ... Pfizer Inc

06/21/18 / #20180169232

Pd-l1 antagonist combination treatments

The present disclosure describes combination therapies comprising an antagonist of programmed death ligand 1 receptor (pd-l1) and another therapeutic agent, and the use of the combination therapies for the treatment of cancer.. . ... Pfizer Inc

06/07/18 / #20180155452

Bispecific heterodimeric diabodies and uses thereof

. . Bispecific heterodimeric diabody molecules and uses thereof in the treatment of cancer. The bispecific heterodimeric diabody molecules comprise two polypeptide chains that associate to form two epitope binding sites recognizing the p-cadherin tumor cell associated antigen and the cd3 t cell antigen.. ... Pfizer Inc

05/31/18 / #20180148420

Novel heterocyclic compounds as inhibitors of vanin-1 enzyme

. . . . Compounds, pharmaceutically acceptable salts thereof are disclosed wherein the compounds have the structure of formula (i) as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.. ... Pfizer Inc

05/10/18 / #20180125958

Immunogenic compositions and uses thereof

. . . . The invention relates to immunogenic compositions comprising a capsular polysaccharide (cp) from streptococcus agalactiae, commonly referred to as group b streptococcus (gbs), conjugated to a carrier protein, and optionally including an aluminum-based adjuvant. The invention further relates to methods for inducing an immune response in subjects against gbs and/or for reducing or preventing invasive gbs disease in subjects using the compositions disclosed herein. ... Pfizer Inc

05/10/18 / #20180125854

Therapeutic nanoparticles comprising a therapeutic agent and methods of making and using the same

The present disclosure generally relates to nanoparticles comprising a substantially hydrophobic acid and a therapeutic agent (1-(4-{[4-(dimethylamino)piperidin-1-yl]carbonyl}phenyl)-3-[4-(4,6-dimorpholin-4-yl-1,3,5-triazin-2-yl)phenyl]urea), or pharmaceutically acceptable salts thereof, and a polymer. Other aspects include methods of making and using such nanoparticles.. ... Pfizer Inc

04/12/18 / #20180099039

Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof

The present invention relates to new immunogenic compositions comprising conjugated streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a s. ... Pfizer Inc

04/05/18 / #20180092925

Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one

The present invention relates to novel polymorphic forms of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one, and to processes for their preparation. Such polymorphic forms may be a component of a pharmaceutical composition and may be used to treat a mammalian disease condition mediated by poly(adp-ribose) polymerase activity including the disease condition such as cancer.. ... Pfizer Inc

03/29/18 / #20180086736

Rorc2 inhibitors and methods of use thereof

The present invention provides compounds, pharmaceutical compositions, methods of inhibiting rorγ activity and/or reducing the amount of il-17 in a subject, and methods of treating various medical disorders using such compounds and pharmaceutical compositions.. . ... Pfizer Inc

03/29/18 / #20180086731

Crystalline forms of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate

This invention relates to a crystalline form of 1-((2r,4r)-2-(1h-benzo[d]imidazol-2-yl)-1-methylpiperidin-4-yl)-3-(4-cyanophenyl)urea maleate, and to pharmaceutical compositions thereof, to intermediates and methods for the production and isolation of such crystalline forms and compositions, and to methods of using such crystalline forms and compositions in the treatment of abnormal cell growth in mammals, especially humans.. . ... Pfizer Inc

03/08/18 / #20180065964

Solid forms of a selective cdk4/6 inhibitor

. . . . This invention relates to the crystalline free base of acetyl-8-cyclopentyl-5-methyl-2-(5-piperazin-1-yl-pyridin-2-ylamino)-8h-pyrido[2,3-d]pyrimidin-7-one, formula (1) having improved properties, to pharmaceutical compositions and dosage forms comprising the free base, and to methods for making and using such compounds, compositions and dosage forms in the treatment of cell proliferative diseases, such as cancer.. . ... Pfizer Inc

03/01/18 / #20180057579

Antagonist antibodies against gdf-8 and uses therefor

The disclosure provides improved neutralizing anti-gdf-8 antibodies capable of substantially higher levels of expression in host cells compared to previous anti-gdf-8 antibodies. Also provided are methods of using compositions comprising such antibodies to increase muscle mass or strength, and to treat or prevent muscular disorders, neuromuscular disorders, metabolic disorders, adipose tissue disorders or bone disorders.. ... Pfizer Inc

03/01/18 / #20180055926

Combination of local and systemic immunomodulative therapies for enhanced treatment of cancer

A method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic immunomodulatory anticancer agent. A further method for the treatment of cancer comprising administration of a therapeutically effective amount of an intralesional chemoablative pharmaceutical composition, or variant of said composition, in combination with a therapeutically effective amount of a systemic targeted anticancer agent. ... Pfizer Inc

02/22/18 / #20180051012

Diacylglycerol acyl transferase 2 inhibitors

Compounds of formula i that inhibit the activity of the diacylglycerol acyltransferase 2 (dgat2) and their uses in the treatment of diseases linked thereto in animals are described herein.. . ... Pfizer Inc

02/15/18 / #20180042926

Diacylglycerol acyltransferase 2 inhibitors

. . Compounds of formula i that inhibit the activity of the diacylglycerol acyltransferase 2 (dgat2) and their uses in the treatment of diseases linked thereto in animals are described herein.. . ... Pfizer Inc

02/08/18 / #20180037644

Anti-il-33 antibodies, compositions, methods and uses thereof

. . The invention provides antibodies, and antigen-binding fragments thereof, that specifically bind to il-33, as well as uses, and associated methods thereof.. . ... Pfizer Inc

02/08/18 / #20180037575

Substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors

Provided herein are substituted 3-azabicyclo[3.1.0]hexanes as ketohexokinase inhibitors, processes to make said compounds, and methods comprising administering said compounds to a mammal in need thereof.. . ... Pfizer Inc

01/25/18 / #20180022783

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in seq id no: 1 and a second polypeptide having the sequence set forth in seq id no: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in seq id no: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in seq id no: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mm histidine, and about 150 mm sodium chloride. ... Pfizer Inc

01/11/18 / #20180011103

Circulating tumor cell assay

Methods for the detection, enumeration and analysis of circulating tumor cells expressing insulin-like growth factor-1 receptors (igf-1r) are disclosed. These methods are useful for cancer screening and staging, development of treatment regimens, and for monitoring for treatment responses, cancer recurrence or the like. ... Pfizer Inc

01/04/18 / #20180002428

Anti-cxcr4 antibodies and antibody-drug conjugates

. . The present invention provides antibodies and related molecules that bind to chemokine receptor 4 (cxcr4). The invention further provides antibody-drug conjugates comprising such antibodies, antibody encoding nucleic acids, and methods of obtaining such antibodies. ... Pfizer Inc

01/04/18 / #20180002330

Methyoxy-substituted pyrrolopyridine modulators of rorc2 and methods of use thereof

The present invention provides methoxy-substituted pyrrolopyridines, pharmaceutical compositions thereof, methods of modulating rorγ activity and/or reducing the amount of il-17 in a subject, and methods of treating various medical disorders using such pyrrolopyridines and pharmaceutical compositions thereof.. . ... Pfizer Inc

01/04/18 / #20180000933

Stable aqueous anti-vascular endothelial growth factor (vegf) antibody formulation

The present invention relates to the field of pharmaceutical formulations of antibodies. Specifically, the present invention relates to a stable liquid antibody formulation and its pharmaceutical preparation and use. ... Pfizer Inc

01/04/18 / #20180000923

Neisseria meningitidis compositions and methods thereof

In one aspect, the invention relates to a composition including a first polypeptide having the sequence set forth in seq id no: 1 and a second polypeptide having the sequence set forth in seq id no: 2. In one embodiment, the composition includes about 120 μg/ml of a first polypeptide including the amino acid sequence set forth in seq id no: 1, 120 μg/ml of a second polypeptide including the amino acid sequence set forth in seq id no: 2, about 2.8 molar ratio polysorbate-80 to the first polypeptide, about 2.8 molar ratio polysorbate-80 to the second polypeptide, about 0.5 mg/ml aluminum, about 10 mm histidine, and about 150 mm sodium chloride. ... Pfizer Inc

01/04/18 / #20180000922

Immunogenic compositions for use in pneumococcal vaccines

An object of the present invention is to provide immunogenic compositions for protection against s. Pneumoniae, in particular against s. ... Pfizer Inc

01/04/18 / #20180000885

Therapeutic nanoparticles with high molecular weight copolymers

The present disclosure generally relates to therapeutic nanoparticles. Exemplary nanoparticles disclosed herein may include about 0.1 to about 40 weight percent of a therapeutic agent and about 10 to about 90 weight percent a diblock poly(lactic) acid-poly(ethylene)glycol copolymer or a diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer, wherein the diblock poly(lactic) acid-poly(ethylene)glycol copolymer comprises poly(lactic) acid having a number average molecule weight of about 30 kda to about 90 kda or the diblock poly(lactic)-co-poly(glycolic) acid-poly(ethylene)glycol copolymer comprises poly(lactic)-co-poly(glycolic) acid having a number average molecule weight of about 30 kda to about 90 kda.. ... Pfizer Inc








ARCHIVE: New 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009



###

This listing is an abstract for educational and research purposes is only meant as a recent sample of applications filed, not a comprehensive history. Freshpatents.com is not affiliated or associated with Pfizer Inc in any way and there may be associated servicemarks. This data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Pfizer Inc with additional patents listed. Browse our Agent directory for other possible listings. Page by FreshPatents.com

###